Cubist begins enrolment in Phase III efficacy studies of Bevenopran

Biopharmaceutical company Cubist Pharmaceuticals has begun enrolment in Phase III efficacy studies designed to assess Bevenopran, previously known as CB-5945, in the treatment of opioid-induced constipation (OIC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news